The pharma industry was unhappy about a rule which prevented U.S. accountants and consultants, and even some in-house staff at pharma companies, from providing services to medical services companies in Russia. Carys Golesworthy explains how this has now changed.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.png00Carys Golesworthyhttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngCarys Golesworthy2023-02-14 10:59:582023-02-14 10:59:58International Pharma Can Now Use U.S.-based Accountants in Russia
On 31 January 2023, the internally circulated version of the European Commission’s far-reaching overhaul of the EU’s pharma legislation was leaked, and published by Politico. Here, initial impressions of the biggest surprises in the document are given by Maarten Meulenbelt, Chris Boyle, and Zina Chatzidimitriadou.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/05/GLS-Blog_Generic-imagery-11.png606833Maarten Meulenbelthttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngMaarten Meulenbelt2023-02-06 16:09:332023-02-08 10:48:46Six Surprises In The Leaked European Pharmaceutical Review
New measures for the security assessment of data transfers from China to other countries could make it harder for international pharma companies with China operations to transfer health data out of the country. Lianying Wang explains.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.png00Lianying Wanghttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngLianying Wang2023-01-24 09:07:512023-02-10 11:19:11It Is Now More Difficult For International Pharma To Transfer Data Out Of China
Josh Hofheimer reports the takeaways from Sidley’s co-hosted pitch day with KoreaBio and BioCentury at the J.P. Morgan Healthcare Conference. The session included key insights on entrepreneurial developments and an investor panel on macroeconomic challenges.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.png00Josh Hofheimerhttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngJosh Hofheimer2023-01-18 17:13:382023-01-26 09:37:15Korean Biotechs Share Their Insights With Sidley At J.P. Morgan Healthcare Conference 2023
Sidley’s 2023 Global Life Sciences Trendspotting Report maps out seven key trends in the life sciences industry globally, and identifies some regional trends in the U.S., China, and Europe which are likely to have global ramifications during the coming year.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.png00GLS Blog Contributorhttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngGLS Blog Contributor2023-01-16 09:07:292023-01-18 18:46:057 Key Trends for the Global Life Sciences Industry in 2023
Decentralized clinical trials are on the rise in the EU and the UK. This month, new EU level guidance on how to conduct them has supplemented existing guidance on the topic. Zina Chatzidimitriadou, Lauren Cuyvers and Bronwyn Tonelli give seven considerations for decentralized trial sponsors in the region.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.png00Lauren Cuyvershttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngLauren Cuyvers2022-12-22 11:08:102022-12-22 11:32:32Navigating Decentralized Clinical Trials In the EU and the UK
The Biden administration is conducting investigations into potential antitrust violations to which the life sciences industry may be particularly vulnerable because having board members sit on more than one company is relatively common. Benjamin Nagin and Kristina Gliklad explain.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/05/GLS-Blog_Generic-imagery-10.png606833Benjamin Naginhttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngBenjamin Nagin2022-11-28 11:04:212023-02-08 10:51:50The U.S. Department of Justice may clamp down on life sciences companies that share board members with alleged competitors
September 24The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK
Archives
Categories
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
International Pharma Can Now Use U.S.-based Accountants in Russia
The pharma industry was unhappy about a rule which prevented U.S. accountants and consultants, and even some in-house staff at pharma companies, from providing services to medical services companies in Russia. Carys Golesworthy explains how this has now changed.
Carys Golesworthy
Washington, D.C.
cgolesworthy@sidley.com
Six Surprises In The Leaked European Pharmaceutical Review
On 31 January 2023, the internally circulated version of the European Commission’s far-reaching overhaul of the EU’s pharma legislation was leaked, and published by Politico. Here, initial impressions of the biggest surprises in the document are given by Maarten Meulenbelt, Chris Boyle, and Zina Chatzidimitriadou.
Maarten Meulenbelt
Brussels
mmeulenbelt@sidley.com
Dr. Chris Boyle
London
cboyle@sidley.com
Zina Chatzidimitriadou
London
zchatzidimitriadou@sidley.com
It Is Now More Difficult For International Pharma To Transfer Data Out Of China
New measures for the security assessment of data transfers from China to other countries could make it harder for international pharma companies with China operations to transfer health data out of the country. Lianying Wang explains.
Lianying Wang
Beijing
lianying.wang@sidley.com
Korean Biotechs Share Their Insights With Sidley At J.P. Morgan Healthcare Conference 2023
Josh Hofheimer reports the takeaways from Sidley’s co-hosted pitch day with KoreaBio and BioCentury at the J.P. Morgan Healthcare Conference. The session included key insights on entrepreneurial developments and an investor panel on macroeconomic challenges.
Josh Hofheimer
jhofheimer@sidley.com
7 Key Trends for the Global Life Sciences Industry in 2023
Sidley’s 2023 Global Life Sciences Trendspotting Report maps out seven key trends in the life sciences industry globally, and identifies some regional trends in the U.S., China, and Europe which are likely to have global ramifications during the coming year.
GLS Blog Contributor
sidleyglsblog@sidley.com
Navigating Decentralized Clinical Trials In the EU and the UK
Decentralized clinical trials are on the rise in the EU and the UK. This month, new EU level guidance on how to conduct them has supplemented existing guidance on the topic. Zina Chatzidimitriadou, Lauren Cuyvers and Bronwyn Tonelli give seven considerations for decentralized trial sponsors in the region.
Lauren Cuyvers
Brussels
lcuyvers@sidley.com
Bronwyn Tonelli
Trainee Solicitor
btonelli@sidley.com
Zina Chatzidimitriadou
London
zchatzidimitriadou@sidley.com
The U.S. Department of Justice may clamp down on life sciences companies that share board members with alleged competitors
The Biden administration is conducting investigations into potential antitrust violations to which the life sciences industry may be particularly vulnerable because having board members sit on more than one company is relatively common. Benjamin Nagin and Kristina Gliklad explain.
Benjamin Nagin
New York
bnagin@sidley.com
Kristina Gliklad
New York
kgliklad@sidley.com
Resources
Upcoming Events
Boston Life Sciences Roundtable
ICCA 2024 Hong Kong Sidley Breakfast Seminar
Data Integrity and Governance Workshop
Sidley Healthcare Investment Conference 2024
Archives
Categories